The Royal College of Psychiatrists describes “7 highlights” from its “sold-out”, and no doubt lucrative, International Congress 2018 which this year was held in Birmingham.
Professor Hamish-McAllister’s declarations of interest can be accessed from the British Association for Psychopharmacology. His declaration of 27th March 2017 confirms that in the previous three years, he had “accepted paid speaking engagements in industry supported symposia” from:
- AstraZeneca,
- Bristol Myers-Squibb,
- Eli Lilly,
- GlaxoSmithKline,
- Janssen-Cilag,
- LivaNova,
- Lundbeck,
- Merck Sharp & Dohme,
- Otsuka,
- Pfizer,
- Pulse,
- Roche,
- Servier,
- SPIMACO,
- Sunovian,
- Wyeth
It would be interesting to know how many of the 2,700 delegates from 54 countries, “more countries were represented than in the World Cup” had “piercing insight” into Professor Hamish McAllister-Williams extensive financial competing interests?
In June 2017, Professor Hamish-McAllister came to the small District General hospital that I work to give a sponsored talk that promoted Brintellix made by Lundbeck. I do not attend sponsored education so I do not know what was said but I was surprised to find such a prominent opinion leader visiting our wee corner of Scotland and I was left reflecting upon the wide influence of a few key individuals.
In October 2017, this invitation by Professor McAllister-Williams was shared to psychiatrists in training. It was described as an “unprecedented educational offer” and had the full support the Royal College of Psychiatrists.